Bison Wealth LLC Has $100,000 Stock Position in Portage Biotech Inc. (NASDAQ:PRTG)

Bison Wealth LLC lessened its position in shares of Portage Biotech Inc. (NASDAQ:PRTG) by 80.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 19,272 shares of the company’s stock after selling 79,249 shares during the quarter. Bison Wealth LLC’s holdings in Portage Biotech were worth $100,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Virtu Financial LLC bought a new position in Portage Biotech in the third quarter worth $73,000. 13.36% of the stock is currently owned by hedge funds and other institutional investors.

Portage Biotech Price Performance

Shares of Portage Biotech stock opened at $10.76 on Friday. Portage Biotech Inc. has a 52-week low of $2.10 and a 52-week high of $23.01. The firm has a market capitalization of $11.29 million, a PE ratio of -0.26 and a beta of 0.54. The company’s fifty day moving average price is $6.24 and its two-hundred day moving average price is $5.32.

Portage Biotech Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.